Although DNA-based cancer vaccines have been successfully tested in mouse models, a major drawback of cancer vaccination still remains, namely that tumour antigens are weak and fail to generate a vigorous immune response in tumour-bearing patients. Genetic technology offers strategies for promoting immune pathways by adding immune-activating genes to the tumour antigen sequence. In this work, we converted a model non-immunogenic antigen into a vaccine by fusing it to domain I of the filamentous bacteriophage coat protein III gene. Vaccination with a DNA construct encoding the domain I fusion generated antigen-specific T helper 1-type cellular immune responses. These results demonstrate that the incorporation of protein III into a DNA vaccine formulation can modulate the gene-mediated immune response and may thus provide a strategy for improving its therapeutic effect.
Introduction
Improvement of vaccine efficacy has become a key goal in the development of DNA vaccination as an antitumour therapy. A prerequisite for successful cancer vaccination is breaking the tolerance to tumour-associated antigens, which represent 'self-antigens' and are therefore poorly immunogenic. Various DNA-fusion vaccine strategies, whereby antigens are genetically linked to immunoenhancing molecules, have been explored. 1 These immuno-activating genes include cytokines, 2 chemokines, 3 costimulatory molecules 4 and pathogen-derived sequences. [5] [6] [7] Bacterial virus particles, such as filamentous bacteriophage, have been found to exhibit an adjuvant-like effect when applied in vaccination strategies. 8 Furthermore, it has been shown that the immune response to single-chain antibody fragments (scFvs) is significantly improved by the fusion or co-administration of fragments of coat protein III of filamentous bacteriophage (M. Larsen et al., submitted). The adjuvant and carrier properties of the functionally fused antibody (FuncFAb) system 9 may be the result of multimerization of the scFv fusions to coat protein III, leading also to potential heteromultimerization (ref. 9 and M. Larsen et al., submitted).
Here, we show that the domain I fragment of coat protein III of the filamentous bacteriophage (DI) can induce immunity when delivered as a fusion gene with an scFv. The DNA immunization efficiently primed the immune system, as indicated by the strong T helper 1 (Th1) humoral and cell-mediated antigen-specific immune response, elicited by the expressed DI fusion protein. 
Materials and methods

Construction of vectors
The DI fragment was amplified from plasmid pKBJ3 9 with primer pair pKBJ3NotI (5 0 -AGGTGCGGCCGCCG GGGCCGCAACTGTTGA-3 0 ) and pKBJ3XbaI (5 0 -AAA ATCTAGACCAGTGAATTCTTATTAATG-3 0 ). The NotI/ XbaI-cleaved polymerase chain reaction (PCR) fragment was ligated into the NotI/XbaI-digested backbone of plasmid p.L36, 10 resulting in p.L36-DI. The sequence was verified using primer BGHreverse (5 0 -TAGAAGGCACAG TCGAGG-3 0 ). Plasmid DNA was purified using the Endofree plasmid megakit (Qiagen, Hilden, Germany).
Expression and purification of recombinant antibodies
L36 is an antilaminin scFv fragment that inhibits angiogenesis both in vitro and in vivo, and was selected from a human phage display library. 10 The expression and purification of non-fused and DI-fused L36 antibodies were performed as described previously. 9 Phage particles from selected clones were used to infect Escherichia coli HB2151 cells. Single colonies were grown overnight at 37°i n 2 · TY medium (16 g of tryptone, 10 g of yeast extract, 5 g of NaCl per liter) supplemented with 100 lg/ml ampicillin and 1% glucose. Five hundred millilitres of 2 · TY medium containing 100 lg/ml ampicillin and 0Á1% glucose was inoculated into 5 ml of the overnight culture and incubated for 4 hr at 37°with shaking. The cultures were induced by the addition of 1 mM isopropylb-D-thiogalactopyranoside (IPTG) and grown overnight at 28°. Periplasmic fractions were prepared by osmotic shock and cleared by centrifugation prior to immobilized metal affinity chromatography (Amersham Biosciences, Uppsala, Sweden). The purified antibodies were verified by western blotting and enzyme-linked immunosorbent assay (ELISA) using the anti-myc 9E10 monoclonal antibody (mAb). Briefly, MaxisorpÒ 96-well plates (Nunc, Roskilde, Denmark) were coated overnight at 4°with laminin-1 (Sigma Biosciences, St Louis, MO) at a concentration of 1 lg/well. After three washes, plates were blocked for 2 hr at room temperature with 4% non-fat dry milk in phosphate-buffered saline (PBS), then antibody derivatives were added (at varying concentrations) for 1 hr at room temperature. After three washes, bound antibody was detected using the 9E10 mAb.
Culture conditions and cell transfections
Human embryonic kidney 293T cells (ATCC CRL-1573) were grown in Dulbecco's modified Eagle's minimal essential medium (DMEM) supplemented with 10% fetal calf serum (FCS) (Invitrogen Life Technologies, Carlsbad, CA). 293T cells were transfected with plasmids pCR3.1, p.L36 or p.L36-DI using Lipofectamine (Invitrogen Life Technologies). Supernatants were collected 48 hr post-transfection, and the secretion of functional scFv was demonstrated by ELISA 10 and western blot, as described above.
Animals and immunizations
Two groups of BALB/c mice (6-8-week-old females; Harlan Ibérica, Barcelona, Spain) were immunized with PBS (n ¼ 4) or recombinant L36 (50 lg) emulsified in 100 ll of incomplete Freund's adjuvant (IFA) (n ¼ 4). Injections were given intraperitoneally (i.p.) on days 0 and 14. Two groups of mice (n ¼ 4) were injected with 50 lg of plasmid DNA (pCR3.1-L36 or pCR3.1-L36-DI). Mice received bilateral injections (25 lg each) into left and right posterior thigh muscles on days 0, 7, 14 and 21. 11 Mice were bled by retro-orbital puncture at regular time-points and plasma was stored at )20°until assayed. All animals were handled in accordance with the guidelines of the Department of Health and Human Services.
Evaluation of immune response
L36-specific antibodies were detected by ELISA, using MaxisorpÒ 96-well plates coated overnight at 4°with recombinant scFv (L36 or B1.8) or bovine serum albumin (BSA) (0Á25 lg/well). After three washes, plates were blocked for 30 min at room temperature with 3% BSA in PBS (BPBS), then diluted sera in 3% BPBS was added and the plates were incubated for 1 hr at room temperature. After three washes, immunoglobulin G (IgG)1 and IgG2a isotypes and total IgG were detected by incubation with anti-mouse IgG1, IgG2a and IgG polyclonal rabbit antibodies (Abcam, Cambridge, UK), respectively. After additional washing, a peroxidase (POD)-conjugated goat anti-rabbit immunoglobulin (Dako, Glostrup, Denmark) was used for detection.
Antigen-specific cytokine assays
Red blood cell-depleted splenocytes (2 · 10 5 ) were plated in 100 ll of RPMI supplemented with 10% FCS in round-bottom 96-well microtitre plates (Corning Inc., Corning, NY). The splenocytes were stimulated with purified bacterial-produced L36 scFv (7Á5 lg/ml), or with medium alone as a control for the baseline level of cytokine synthesis. After 72 hr, supernatants were harvested and assayed for interleukin-4 (IL-4) and interferon-c (IFN-c) using commercially available ELISA kits (Endogen, Woburn, MA). Antigen-specific cytokine secretion was obtained by subtracting the cytokine content of splenocytes incubated with complete medium alone.
Serum cytokine determination
Serum cytokine levels were determined using the cytometric bead array kit (Bender MedSystems, Vienna, Austria) according to the manufacturer's instructions. Cytometric analysis was performed by FACScalibur (Becton Dickinson, Bedford, MA) and data analysis was achieved using the software BMS-FFS (Bender MedSystems).
Results
Construction of a DI-fused L36-encoding mammalian expression vector
We have previously described and characterized the human cytomegalovirus (hCMV)-driven mammalian expression vector, p.L36, containing the antilaminin-1 L36 scFv immunoglobulin. 10 In order to study the ability of mammalian cells to secrete a filamentous phage gene III DI-fused scFv immunoglobulin, we constructed the plasmid p.L36-DI, containing the human oncostatin M leader sequence followed by L36 scFv fused to the first 80 translated nonleader sequence codons of gene III (Fig. 1a) . Transfection of human 293T cells with plasmid p.L36 or p.L36-DI resulted in the secretion of functional antibodies. The secreted non-fused and DI-fused scFvs bound specifically to their cognate antigen (laminin-1), as determined by ELISA (Fig. 1b) . Antibody was not detected in the cell culture supernatant of 293T cells transfected with pCR3.1 control plasmid (Fig. 1b,c) . Western blot analysis of conditioned medium from 293T cells transfected with p.L36 or p.L36-DI plasmids demonstrated that the migration pattern of the secreted proteins was consistent with the predicted molecular weight (Fig. 1c) . Under reducing conditions, the migration patterns of both mammalian-and bacterialproduced non-fused L36 antibodies were similar, whereas the mammalian-produced DI-fused L36 scFv was slightly larger than the bacterial-produced DI fusion, probably owing to differences in the glycosylation pattern. In fact, DI has a predicted N-glycosylated site (residues 57-60). 12 
Vaccination and immune response
Mice were immunized with plasmids encoding non-fused and DI-fused L36 scFvs, and their antigen-specific humoral responses were compared with those of the mice injected with purified non-fused L36 scFv mixed with IFA. Anti-L36 IgG was detected in mice immunized with purified non-fused scFv on day 14, and with plasmid p.L36-DI on day 28, after the third DNA injection (Fig. 2a,b) . The anti-L36 IgG induced by both the purified non-fused L36 scFv and the plasmid DNA encoding the DI-fused L36 showed no reactivity by ELISA with an unrelated scFv derived from the hapten-specific mAb B1.8 (data not shown). Immunization with plasmid containing only the scFv sequence failed to induce detectable anti-L36 scFv immunoglobulin (Fig. 2a) . In mice immunized with p.L36-DI, the subclass distribution of IgG1 and IgG2a showed dominance of the IgG2a isotype (Fig. 3a) characteristic of a Th1-type response. In mice immunized with purified L36 scFv mixed with IFA, the subclass distribution of IgG1 and IgG2a showed higher IgG1 than IgG2a levels, although both subclasses were prominent (Fig. 3a) . A similar subclass distribution of IgG1 and IgG2a was observed in mice immunized with purified L36 scFv alone, or fused to the DI of protein III (M. Larsen et al., submitted).
Antigen-specific cytokine production
The cellular response induced in mice by immunization with p.L36-DI was also measured. For that purpose, we examined the cytokine production profile of antigen-specific immune cells. Splenic mononuclear cells were obtained 1 week after the last plasmid DNA immunization (day 28) and were stimulated in vitro with the purified non-fused L36 scFv. After 72 hr, the supernatants were harvested and assayed for both IL-4 and IFN-c. The results, depicted in Fig. 3 , indicated that immunization with p.L36-DI stimulates the production of large quantities of IFN-c (Fig. 3b) , but almost undetectable levels of IL-4 (Fig. 3c) . In contrast, high levels of IL-4 were observed in the supernatants of splenocytes obtained from animals immunized with purified non-fused L36 scFv mixed with IFA (Fig. 3c) . In these supernatants, IFN-c was detected at considerable levels.
Cytokine levels in the serum of immunized mice
Sera obtained when the mice were killed were also assayed for cytokine content by using a cytometric bead array kit. As seen in Fig. 3d , treatment with p.L36-DI resulted in significantly elevated levels of IFN-c. IL-4 ( Fig. 3e ) was almost undetectable in mice immunized with p.L36-DI, in contrast to the animals immunized with purified non-fused L36 scFv.
Discussion
We have demonstrated the feasibility of using the Nterminal domain of filamentous bacteriophage coat protein III as an adjuvant molecule in a genetic vaccination protocol. We converted a model, non-immunogenic scFv fragment into a vaccine by fusing it to the first 80 residues of protein III. With the appropriate immunization schedule, a naked DNA plasmid vaccine encoding the scFv-DI fusion induced a Th1 immune response, characterized by a dominant L36-specific IgG2a humoral response and high levels of IFN-c produced by splenic T cells. Immunity was not elicited by naked DNA plasmid encoding non-fused sFv. Immunization with purified non-fused scFv protein and adjuvant elicited a mixed Th1/Th2 cellular immune response. Th1 immunity has classically been considered to be more attractive in a therapeutic setting, given that the associated high cytotoxic T-lymphocyte (CTL) activity plays a key role in the host defence against tumours and viral infections.
The differences observed in the present study could be explained by the fact that plasmid DNA uptake results in an endogenous synthesis of the encoded protein and its subsequent association with major histocompatibility complex (MHC) class I molecules; in contrast, administered soluble proteins are processed predominantly through the exogenous pathway. Activation of the immune response is also known to be influenced by both the nature and molecular form of the antigen, with large aggregates being particularly immunogenic. 13 Previous results suggest that aggregated antigen amplifies a Th1-type response, already activated by the cytokine environment generated by the injection of DNA.
14 Induction of Th1-type dominant responses has also been noted using genetic fusions of aggregating plant viral coat proteins to both peptides and scFvs. 7, 15, 16 In our model, multimerization of the scFv is accomplished by linking the antibody fragment to domain I of coat protein III when examined in vitro. 9 This fusion design has the added advantage of functioning as a 'builtin' adjuvant, creating a direct route from reactive generation to vaccine development.
